Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

Merck & Co forecasts lower 2026 sales and profits due to post-patent challenges for key drugs like Januvia, despite strong performance from Keytruda. The company's proactive measures include ...

Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...